Table 1: NOVEL DME THERAPIES IN DEVELOPMENT AND UPCOMING DEVELOPMENT MILESTONES Table 2: TREATMENT OF DIABETIC MACULAR EDEMA IN THE US Table 3: STUDIES OF ANTI-VEGF AGENTS AND CHANGE IN BCVA IN DME PATIENTS Table 4: STUDIES OF STERIOD AGENTS AND CHANGE IN BCVA IN DME PATIENTS Table 5: NEW TRIAMCINOLONE ACETONIDE (MAQAID) DETAILS Table 6: INDIRECT COMAPRISON OF MAQAID WITH OTHER OPHTHALMIC STERIODS FOR DME Table 7: NOVEL DME THERAPIES IN DEVELOPMENT Table 8: DME PIPELINE -PHASE III Table 9: DME PIPELINE -PHASE II Table 10: DME PIPELINE -PHASE I Table 11: DME PIPELINE -PRE-CLINICAL

Figures 1: PROGRESSION OF DME Figures 2: PATHOLOGY OF DME VISIBLE ON OCT IMAGING Chart 1: NUMBER OF DME TREATED PATIENTS IN THE US (2014-2019) Chart 2: US DME THERAPEUTIC MARKET SIZE IN 2019 AND 2025 Chart 3: US ANTI-VEGF THERAPEUTIC MARKET SIZE, 2014-2019 Chart 4: VALUE AND VOLUME SHARES OF CURRENT OPHTHALMIC ANTI- VEGF’S IN THE US Chart 5: US DME ANTI-VEGF THERAPEUTIC MARKET SIZE – 2019 Chart 6: US DME ANTI-VEGF THERAPEUTIC MARKET SIZE, 2020-2025 Chart 7: US DME-ANTI-VEGF OPHTHALMIC VALUE MARKET SHARE IN 2025 Chart 8: US STERIOD OPHTHALMIC MARKET SIZE BY VALUE, 2014-2019 Chart 9: US STERIOD OPHTHALMIC MARKET SIZE BY VOLUME, 2014-2019 Chart 10: US DME STERIODS THERAPEUTIC MARKET SIZE IN 2019 AND IN 2025